BIOGEN INC. Notes Payable
BIOGEN INC. (BIIB) had Notes Payable of $6.29 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:NotesPayable · last filed 2026-04-29
- 2026-03-31: Notes Payable $6.29B.
- 2025-12-31: Notes Payable $6.29B.
- 2025-09-30: Notes Payable $6.29B.
- 2025-06-30: Notes Payable $6.28B.
| Period end | Notes Payable | Notes Payable as first filed |
|---|---|---|
| 2026-03-31 | $6.29B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $6.29B 10-Q · filed 2026-04-29 | |
| 2025-09-30 | $6.29B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $6.28B 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $6.30B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $6.30B 10-Q · filed 2025-10-30 | |
| 2024-09-30 | $6.29B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $6.29B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $6.54B 10-Q · filed 2024-04-24 | |
| 2023-12-31 | $6.94B 10-Q · filed 2024-10-30 | |
| 2023-09-30 | $6.29B 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $6.28B 10-Q · filed 2023-07-25 | |
| 2023-03-31 | $6.28B 10-Q · filed 2023-04-25 | |
| 2022-12-31 | $6.28B 10-Q · filed 2023-11-08 | |
| 2022-09-30 | $6.28B 10-Q · filed 2022-10-25 | |
| 2022-06-30 | $7.28B 10-Q · filed 2022-07-20 | |
| 2022-03-31 | $7.28B 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $7.27B 10-Q · filed 2022-10-25 | |
| 2021-09-30 | $7.27B 10-Q · filed 2021-10-20 | |
| 2021-06-30 | $7.27B 10-Q · filed 2021-07-22 | |
| 2021-03-31 | $7.27B 10-Q · filed 2021-04-22 | |
| 2020-12-31 | $7.43B 10-Q · filed 2021-10-20 | |
| 2020-09-30 | $7.42B 10-Q · filed 2020-10-21 | |
| 2020-06-30 | $7.42B 10-Q · filed 2020-07-22 | |
| 2020-03-31 | $5.96B 10-Q · filed 2020-04-23 | |
| 2019-12-31 | $5.95B 10-Q · filed 2020-10-21 | |
| 2019-09-30 | $5.95B 10-Q · filed 2019-10-22 | |
| 2019-06-30 | $5.95B 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $5.94B 10-Q · filed 2019-04-24 | |
| 2018-12-31 | $5.94B 10-Q · filed 2019-10-22 | |
| 2018-09-30 | $5.93B 10-Q · filed 2018-10-23 | |
| 2018-06-30 | $5.93B 10-Q · filed 2018-07-24 | |
| 2018-03-31 | $5.93B 10-Q · filed 2018-04-24 | |
| 2017-12-31 | $5.94B 10-Q · filed 2018-10-23 | |
| 2017-09-30 | $6.49B 10-Q · filed 2017-10-24 | |
| 2017-06-30 | $6.50B 10-Q · filed 2017-07-25 | |
| 2017-03-31 | $6.50B 10-Q · filed 2017-04-25 | |
| 2016-12-31 | $6.50B 10-Q · filed 2017-10-24 | |
| 2016-09-30 | $6.52B 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $6.52B 10-Q · filed 2016-07-21 | |
| 2016-03-31 | $6.52B 10-Q · filed 2016-04-21 | |
| 2015-12-31 | $6.51B 10-Q · filed 2016-10-26 | |
| 2015-09-30 | $6.51B 10-Q · filed 2015-10-21 | |
| 2015-06-30 | $579.50M 10-Q · filed 2015-07-24 | |
| 2015-03-31 | $583.90M 10-Q · filed 2015-04-24 | |
| 2014-12-31 | $583.40M 10-Q · filed 2015-10-21 | $585.20M 10-Q · filed 2015-04-24 |
| 2014-09-30 | $587.20M 10-Q · filed 2014-10-22 | |
| 2014-06-30 | $589.50M 10-Q · filed 2014-07-23 | |
| 2014-03-31 | $594.60M 10-Q · filed 2014-04-23 | |
| 2013-12-31 | $595.90M 10-Q · filed 2014-10-22 | |
| 2013-09-30 | $597.00M 10-Q · filed 2013-10-28 | |
| 2013-06-30 | $597.70M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $802.30M 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $1.05B 10-Q · filed 2013-10-28 | |
| 2012-09-30 | $1.06B 10-Q · filed 2012-10-25 | |
| 2012-06-30 | $1.06B 10-Q · filed 2012-07-24 | |
| 2012-03-31 | $1.06B 10-Q · filed 2012-05-01 | |
| 2011-12-31 | $1.06B 10-Q · filed 2012-10-25 | |
| 2011-09-30 | $1.06B 10-Q · filed 2011-10-28 | |
| 2011-06-30 | $1.07B 10-Q · filed 2011-07-26 | |
| 2011-03-31 | $1.08B 10-Q · filed 2011-04-21 | |
| 2010-12-31 | $1.08B 10-Q · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |